Comirnaty COVID-19 vaccine: how BioNTech’s shot is used

Comirnaty, the mRNA COVID-19 vaccine from BioNTech and Pfizer, remains a key option for protection against severe illness for eligible people in the United States. Here is how it works and where it fits today.

Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, received the first full FDA approval for an mRNA COVID-19 vaccine on 08/23/2021 for individuals 16 years and older FDA, 08/23/2021. The same product continues to be updated for circulating variants CDC, 02/28/2024.

As of: 05/20/2026 | Reading time: approx. 9 minutes

By the AD HOC NEWS editorial team - specialized in product-focused market coverage.

At a Glance

• Product: Comirnaty COVID-19 vaccine
• Category: mRNA COVID-19 vaccine
• Brand/Manufacturer: BioNTech and Pfizer
• Primary Use Cases: Vaccination against COVID-19 to reduce risk of severe disease
• Availability: Available in the United States for eligible age groups via healthcare providers and pharmacies
• Core Markets: United States, European Union, and other regions with local regulatory authorizations

What Comirnaty COVID-19 vaccine Is and How It Works

Comirnaty is an mRNA vaccine that delivers genetic instructions for cells to produce the SARS-CoV-2 spike protein, prompting an immune response without using live virus CDC, 08/31/2022.

The vaccine uses lipid nanoparticles to protect the fragile mRNA and help it enter cells. After the cells make the spike protein, the mRNA is broken down and does not interact with a person’s DNA FDA, 01/04/2022.

Recent formulations of Comirnaty are updated to target currently circulating variants, and US recommendations focus on single-dose vaccination for most previously vaccinated individuals, with specific guidance by age and risk group CDC, 03/14/2024.

Why Comirnaty Matters for US Consumers and Industry

In the United States, Comirnaty is one of the main COVID-19 vaccines used to reduce the risk of severe illness, hospitalization, and death among vaccinated individuals, especially older adults and people with underlying conditions CDC, 12/08/2023.

For employers, hospitals, and long-term care providers, access to an FDA-approved and continually updated vaccine supports infection control strategies and helps maintain staffing and operations, especially during respiratory virus seasons CDC, 10/06/2023.

Comirnaty in the US and Global Market

Comirnaty is distributed in the US through pharmacies, physician offices, community health centers, and public clinics under federal and state vaccination programs and commercial distribution Pfizer, 12/15/2023.

Outside the US, Comirnaty is authorized in the European Union and many other countries according to local regulators, using variant-adapted formulations that follow guidance from agencies such as EMA and national health authorities EMA, 10/18/2023.

• mRNA-based vaccine using lipid nanoparticles
• Targets SARS-CoV-2 spike protein to trigger immune response
• Updated formulations address circulating variants
• Used in the US for eligible age groups
• Authorized in multiple global markets

Frequently Asked Questions About Comirnaty COVID-19 vaccine

Who can receive Comirnaty in the United States?
Eligibility for Comirnaty in the US depends on age, prior vaccination, and risk factors, with current schedules starting from 6 months of age and detailed guidance published by CDC CDC, 03/14/2024.

Does Comirnaty change your DNA?
According to FDA and CDC, the mRNA in Comirnaty does not enter the cell nucleus where DNA is located and is broken down by the body after it is used to make spike protein FDA, 01/04/2022.

How is Comirnaty stored and handled?
Healthcare providers must store Comirnaty vials at specified cold-chain temperatures and follow detailed preparation and administration instructions from the FDA-authorized prescribing information and CDC clinical guidance Pfizer, 09/11/2023.

BioNTech SE, based in Mainz, Germany, is a biotechnology company that co-developed Comirnaty with Pfizer and remains focused on mRNA-based medicines, including vaccines and oncology therapeutics.

The companys American Depositary Shares are listed on Nasdaq under the ticker BNTX, and the issuer ISIN is US09075V1026, which serves as a unique identifier for the securities in global markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.